Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Netscientific LSE:NSCI London Ordinary Share GB00B9F4MT28 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 27.90p 4,860 08:00:00
Bid Price Offer Price High Price Low Price Open Price
27.00p 28.80p 27.90p 27.90p 27.90p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.39 -9.58 -13.60 21.9

Netscientific (NSCI) Latest News

More Netscientific News
Netscientific Takeover Rumours

Netscientific (NSCI) Share Charts

1 Year Netscientific Chart

1 Year Netscientific Chart

1 Month Netscientific Chart

1 Month Netscientific Chart

Intraday Netscientific Chart

Intraday Netscientific Chart

Netscientific (NSCI) Discussions and Chat

Netscientific Forums and Chat

Date Time Title Posts
01/12/201813:14NetScientific PLC717

Add a New Thread

Netscientific (NSCI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Netscientific trades in real-time

Netscientific (NSCI) Top Chat Posts

Netscientific Daily Update: Netscientific is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NSCI. The last closing price for Netscientific was 27.90p.
Netscientific has a 4 week average price of 26.40p and a 12 week average price of 26.40p.
The 1 year high share price is 75.50p while the 1 year low share price is currently 26.40p.
There are currently 78,561,866 shares in issue and the average daily traded volume is 5,205 shares. The market capitalisation of Netscientific is £21,918,760.61.
escapetohome: An unacceptable share price performance. Come on Netscientific , lets do the jiggle jiggle!
che7win: Bottom line, quite literally is where is the funding coming from?They either sell down some investments, list them on a market or raise cash.They have a lot of management and staff, top heavy in my opinion and that cash is running out. You have failed to consider that, the more the company leaves this to the side, the lower the share price is going and the bigger the dilution.See, I know your game here, you have been hoping for good news and as happened in the past, a gang of rampers pumped this up very quickly as its illiquid, very illiquid, many would jump to get out. I know this because I do research.
che7win: That research never came, I guess the market is worried about the high costs, near term losses and possible dilution if cash burn continues.For that, the company needs a high share price, but usually the people running these types of businesses are academics and not money people...
mortimer7: RNS today, very positive news IMO:-
sharestobuy: 13.5 x current share price. That's ridiculous. You'd be looking at around £25.00 a share??
protean: Huge stored potential value from key assets according to Investec. 13.5x current share price. hTTp://
protean: Nice bit of news and hopefully just the start. From the recent Investec note: "Once newsflow on commercialisation, licencing deals or regulatory development occurs with key portfolio assets, we believe the share price looks set to re-rate materially." hTTp://
protean: WANDA and Vortex potential certainly something to attract investors: "To us, both technologies are capable of delivering returns equivalent to c.5x Netscientific's share price..." hTTp:// No wonder Woodford was keen to get his hands on so many shares.
themadstork: AGM notes: Myself and Baron Day Trading (baron83 on LSE) attended the AGM yesterday in Kensington. Firstly Dr Martelet (CEO) gave a short presentation -Recently taken over as CEO and will be implementing a review of the portfolio to be completed by September -Disposal of non-core assets -Focus on 5 core companies: Wanda (remote diagnostic software); Vortex (indentifcation of Circulating Tumor Cells for cancer diagnosis); Glycotest(Non-invasive tests for liver cancer); Glucosense (wearable glucose monitoring); G-Tech Medical (wearable tech for gastric disorder diagnosis) -Hugely increased and much more regular updates to the market Sir Richard (Chairman, former Glaxo CEO) chaired the meeting and ran through the resolutions proposed, all of which were pretty much formalities and all passed unanimously. He then asked for questions. Baron and I raised the issue of lack of communication to the market. All of the board, and especially Dr Martelet, strongly agreed that communication had been lacking in the past and this would be addressed. We specifically mentioned lack of broker research notes and it was confirmed that several would be published in the near future. I raised the point of liquidity and the board confirmed they were aware of the issue due to the extremely small free float. As mentioned in the RNS, they will be looking to fundraise at some point in the next 12 months, however they will obviously be hoping to do so at a much higher share price and with participation from the existing II holders. We then spent some time talking to the board one on one. Observations: The board seemed extremely engaged and all were willing to chat to Baron and I regarding the points we'd raised. Dr Martelet seemed especially aware of the need for an increase in newsflow and PR from the company in order to raise the company's market profile. Dr Boyce-Jacino (head of US operations) and David Gough (Head of Europe) were also very willing to chat and seemed to be confident that interest would increase in the near future. I believe that Baron and I were the only two private shareholders present. The rest were representatives from the big IIs that hold most of the shares. Think this reflects the nature of the shareholder base and absolutely tiny free float. I suspect that the concerns of retail investors have never really been raised to the board in past past, but they certainly have now! Consequently I think we should see a big push to get the story out there which should hopefully lead to greater volumes traded and result in a higher share price. Lastly, and most importantly, there were loads of free sandwiches! Conclusions -Board is fully aware of shareholder concerns, believes the company is significantly undervalued and will act in our interests -Newsflow will increase significantly near term. Wanda and Vortex still on track for near term commercial launch. -Will be a greater effort made to explain the NSCI story to investors -Broker notes will be published -Liquidity will improve medium term I am very happy to hold my stake and am looking forward to the near and medium term especially here.
cinques: Hyper Al, The stake that NSCI has in PDS is 14.85% of PDS's share capital. NSCI also have warrants to buy more PDS shares. The warrants were valued at £100k in the EoY NSCI accounts. I have no idea what warrants there are, but let's say that, including the warrants, NSCI own 20% of PDS. See page 37 of the 2014 annual report - link on this page: NSCI have just under 36,000,000 shares in issue. The share price jumped 67.5p today, or about £24m added to the NSCI MCap. This implies about £120m was added to PDS's value. If PDS really has a cure for HPV induced cancers, £120m is peanuts. However, this is just a Phase 1 trial and there are more steps to go. I can see a higher price tomorrow. I don't own any of these, but I'll be buying some in the morning.
Netscientific share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181212 10:31:25